Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Phase 2

Completed

Conditions: Germ Cell Tumors

First Posted Date: 2009-03-18

Last Posted Date: 2021-01-12

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 101

Registration Number: NCT00864318

Locations: 🇫🇷
Hopital St André, Bordeaux, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

and more 8 locations

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Phase 2

Completed

Conditions: Carcinoma, Non-small Cell Lung

First Posted Date: 2009-03-13

Last Posted Date: 2015-12-02

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 37

Registration Number: NCT00861627

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Male Breast Carcinoma
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7
Triple-Negative Breast Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Biological: Bevacizumab
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2009-03-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 454

Registration Number: NCT00861705

Locations: 🇺🇸
Wellstar Kennestone Hospital, Marietta, Georgia, United States
🇺🇸
Swedish American Hospital, Rockford, Illinois, United States
🇺🇸
HaysMed, Hays, Kansas, United States

and more 441 locations

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: CT-322
Drug: Bevacizumab
Drug: Bevacizumab placebo (ie saline solution)

First Posted Date: 2009-02-25

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 255

Registration Number: NCT00850577

Locations: 🇺🇸
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇺🇸
Clintell, Inc., Skokie, Illinois, United States
🇺🇸
North Canton Medical Clinic Center, Canton, Ohio, United States

and more 19 locations

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Phase 3

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Farletuzumab
Drug: Carboplatin
Drug: Taxane
Drug: Farletuzumab-matched placebo

First Posted Date: 2009-02-24

Last Posted Date: 2022-12-30

Lead Sponsor: Morphotek

Target Recruit Count: 1100

Registration Number: NCT00849667

Locations: 🇺🇸
Hematology Oncology P.C., Stamford, Connecticut, United States
🇺🇸
Loyola University Chicago, Maywood, Illinois, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States

and more 339 locations

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Phase 1

Completed

Conditions: Locally Advanced, Metastatic Solid Tumors

Interventions: Drug: MK-2206
Drug: docetaxel
Drug: carboplatin
Drug: erlotinib
Drug: corticosteroid
Drug: paclitaxel

First Posted Date: 2009-02-20

Last Posted Date: 2019-11-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 77

Registration Number: NCT00848718

Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine hydrochloride
Drug: paclitaxel

First Posted Date: 2009-02-06

Last Posted Date: 2013-09-17

Lead Sponsor: Warwick Medical School

Target Recruit Count: 88

Registration Number: NCT00838656

Locations: 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
🇬🇧
Good Hope Hospital, Birmingham, England, United Kingdom

and more 1 locations

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: E7080
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-01-30

Last Posted Date: 2015-04-30

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT00832819

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cetuximab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2009-01-26

Last Posted Date: 2013-11-06

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 601

Registration Number: NCT00828841

Locations: 🇺🇸
Family Medicine of Vincennes, Vincennes, Indiana, United States

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Phase 1

Withdrawn

Conditions: Lymphoma

First Posted Date: 2009-01-26

Last Posted Date: 2013-08-26

Lead Sponsor: Cancer Research UK

Registration Number: NCT00829205

Locations: 🇬🇧
Derriford Hospital, Plymouth, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom
🇬🇧
Barts and the London NHS Trust, London, England, United Kingdom

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy